Background: The COVID-19 vaccine-related Guillain-Barré syndrome (GBS) has been described for both messenger-RNA vaccine and adenovirus-vectored types in a few cases with great public concern and the necessity to inform physicians about the variations of its presentations given its life-threatening consequences.
Case Presentation: This case series highlighted the presentation with GBS following different COVID-19 vaccinations in seven cases with ages ranging from 29 to 59 years. Three patients received the AstraZeneca vaccine, two received the Pfizer vaccine, one received Sinopharm, and one received the Janssen vaccine. Latency ranged from 5 to 60 days and cases achieved either partial or complete improvement after treatment trials. Patients responded to plasmaphereses, but not pulse steroid therapy.
Conclusion: This case series highlights the variable presentations and outcomes of GBS following different COVID-19 vaccination from one center. The early identification and appropriate management of such cases can lead to better outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734843 | PMC |
| http://dx.doi.org/10.1186/s41983-022-00582-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inflammation and Occlusive Retinal Vasculitis Post Faricimab.
JAMA Ophthalmol
January 2025
Truhlsen Eye Center, Department of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha.
Importance: Randomized clinical trials have shown the safety and efficacy of faricimab as a novel vascular endothelial growth factor and angiopoietin-2 inhibitor in the treatment of neovascular age-related macular degeneration (nAMD) and macular edema of various etiologies. However, more rare adverse events may not be considered in clinical trials.
Objective: To describe 3 eyes that developed irreversible vision loss following initial mild intraocular inflammation (IOI) to faricimab.
Treatment of hyponatremia: comprehension and best clinical practice.
Clin Exp Nephrol
January 2025
Division of Endocrinology and Metabolism, Department of Medicine, Georgetown University, 4000 Reservoir Rd NW, Washington, DC, 20007, USA.
This review article series on water and electrolyte disorders is based on the 'Electrolyte Winter Seminar' held annually for young nephrologists in Japan. The seminar features dynamic case-based discussions, some of which are included as self-assessment questions in this series. The second article in this series focuses on treatment of hyponatremia, a common water and electrolyte disorder frequently encountered in clinical practice.
View Article and Find Full Text PDFEosinophilic Myocarditis: A Concise Review.
Curr Cardiol Rep
January 2025
Division of Heart and Vascular, Metrohealth Medical Center, 2500 Metrohealth Dr, Cleveland, OH, 44109, USA.
Purpose Of Review: Eosinophilic myocarditis (EM) is a rare and heterogeneous form of inflammatory heart disease that can present with a wide range of severity. Current literature is limited to case reports or small case series that outline the evaluation process, disease course, and the nonstandardized treatments trialed. This review aims to concisely summarize the current literature on EM including an update on maintenance therapy for refractory or recurrent disease.
View Article and Find Full Text PDFOccupational histories in neuropathologically confirmed multiple system atrophy.
Clin Auton Res
January 2025
Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Purpose: This study examined occupational histories in multiple system atrophy to identify environmental associations of potential relevance to disease causation.
Methods: A total of 270 neuropathologically confirmed cases of multiple system atrophy obtained from the Mayo Clinic Brain Bank for neurodegenerative disorders in Jacksonville, Florida, were included in this case-control study. Demographic and disease information was collected from medical records.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!